Cardlytics (CDLX) Common Equity (2016 - 2026)

Cardlytics has reported Common Equity for 11 years, with the latest figure at -$4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 106.25% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$4.0 million (down 106.25% YoY), and the FY2025 full-year result was -$6.5 million, down 109.3% from the prior year.
• Common Equity for Q1 2026 stood at -$4.0 million, up from -$6.5 million in the prior quarter.
• The five-year high for Common Equity was $711.7 million in Q1 2022, with the low at -$6.5 million in Q4 2025.
• Historically, Common Equity has averaged $209.0 million across 5 years, with a median of $199.1 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity decreased 4.46% — and 2025, when it tumbled 109.3%.
• Cardlytics' Common Equity stood at $211.6 million in 2022, then plunged by 36.3% to $134.8 million in 2023, then tumbled by 48.08% to $70.0 million in 2024, then plunged by 109.3% to -$6.5 million in 2025, then jumped by 38.49% to -$4.0 million in 2026.
• The last three Common Equity figures came in at -$4.0 million (Q1 2026), -$6.5 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.